Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Yasuaki Muramatsu"'
Autor:
Kanako Kikuchi, Akihiro Hirata, Yoshinobu Saito, Manabu Nakamura, Yasuaki Muramatsu, Kento Tabira, Tomoki Manabe, Kentaro Oka, Mizuki Sato, Yuko Oguma
Publikováno v:
BMJ Open, Vol 14, Iss 6 (2024)
Objectives Numerous reports have described injuries and illnesses in competitive athletes, but studies on leisure-time physical activity and associated adverse events in the general population have not been adequately reviewed. This study aimed to su
Externí odkaz:
https://doaj.org/article/a59521a5fde240eb8e8388517f9eb1c6
Publikováno v:
Breast, Vol 70, Iss , Pp 1-7 (2023)
Purpose: The optimal treatment following endocrine therapy (ET) plus a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) has not been established. We aimed to investigate treatment patterns and time to treatment failure (TTF) of subsequent therapy afte
Externí odkaz:
https://doaj.org/article/1e0f5ed4fb38406e9e37439d595dbcab
Autor:
Masato Takahashi, Norikazu Masuda, Reiki Nishimura, Kenichi Inoue, Shinji Ohno, Hiroji Iwata, Satoshi Hashigaki, Yasuaki Muramatsu, Yoshiko Umeyama, Masakazu Toi
Publikováno v:
Cancer Medicine, Vol 9, Iss 14, Pp 4929-4940 (2020)
Abstract Palbociclib is a highly selective, reversible, oral inhibitor of cyclin‐dependent kinases 4 and 6 that is approved to treat hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer. An open‐l
Externí odkaz:
https://doaj.org/article/3f132e5f207c43dc8551b28f7407faeb
Publikováno v:
Cancer Research. 83:P4-01
Background: PAL is a first-in-class cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) for the treatment of HR+/HER2− ABC. Two CDK4/6is are currently available in Japan; PAL and abemaciclib (ABE). CDK4/6i+endocrine therapy (ET) has shown significant c
Publikováno v:
Future oncology (London, England). 18(17)
Aim: To reveal the treatment patterns of palbociclib and complete blood count (CBC) monitoring in a Japanese real-world setting. Materials & methods: Deidentified data of patients with advanced breast cancer who received palbociclib from 2017 to 2020
Autor:
Satoshi Hashigaki, Masakazu Toi, Yoshiaki Rai, Kenichi Inoue, Hiroji Iwata, Yasuaki Muramatsu, Chikako Shimizu, Shinji Ohno, Shoichiro Ohtani, Norikazu Masuda, Hirofumi Mukai, Yoshiko Umeyama
Publikováno v:
Breast Cancer (Tokyo, Japan)
BackgroundIn the double-blind, phase 3 PALOMA-2 and PALOMA-3 studies, palbociclib plus endocrine therapy (ET) demonstrated significant improvement in progression-free survival versus placebo plus ET in patients with hormone receptor‒positive/human
Autor:
Kenichi Inoue, Norikazu Masuda, Shinji Ohno, Reiki Nishimura, Masakazu Toi, Satoshi Hashigaki, Hiroji Iwata, Masato Takahashi, Yasuaki Muramatsu, Yoshiko Umeyama
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 9, Iss 14, Pp 4929-4940 (2020)
Cancer Medicine, Vol 9, Iss 14, Pp 4929-4940 (2020)
Palbociclib is a highly selective, reversible, oral inhibitor of cyclin‐dependent kinases 4 and 6 that is approved to treat hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer. An open‐label, sin
Autor:
Hirofumi Mukai, Yasuaki Muramatsu, Norikazu Masuda, Yoshiko Umeyama, Masakuzu Toi, Kenichi Inoue, Hiroji Iwata, Satoshi Hashigaki, Yuko Mori, Shinji Ohno, Yoshiaki Rai
Publikováno v:
Breast Cancer (Tokyo, Japan)
BackgroundThe cyclin-dependent kinase 4/6 (CDK4/6) inhibitor palbociclib, in combination with endocrine therapy (ET), significantly prolonged progression-free survival in women with hormone receptor–positive, human epidermal growth factor receptor
Autor:
Yasuaki Muramatsu, Takashi Nagasawa, Satoshi Hashigaki, Shoichiro Ohtani, Shozo Ohsumi, Hiroji Iwata, Norikazu Masuda, Reiki Nishimura, Masato Takahashi, Masakazu Toi, Chikako Shimizu, Dongrui R. Lu, Nobuaki Sato, Yoshiko Umeyama, Yuko Mori, Shinji Ohno, Yutaka Yamamoto, Hirofumi Mukai
Publikováno v:
International Journal of Clinical Oncology
Background In PALOMA-2, palbociclib–letrozole significantly improved progression-free survival (PFS) vs placebo–letrozole in women with estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breas
Autor:
Norikazu, Masuda, Kenichi, Inoue, Rikiya, Nakamura, Yoshiaki, Rai, Hirofumi, Mukai, Shinji, Ohno, Fumikata, Hara, Yuko, Mori, Satoshi, Hashigaki, Yasuaki, Muramatsu, Takashi, Nagasawa, Yoshiko, Umeyama, Xin, Huang, Hiroji, Iwata
Publikováno v:
International Journal of Clinical Oncology
Background In the double-blind, phase 3 PALOMA-3 study, palbociclib–fulvestrant significantly prolonged progression-free survival versus placebo–fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor